Orbital ATK, Inc. OA
Set alert
134.50 0.00 0.00%
At close · Jun 28
134.47 Day range 134.51
52-week range unavailable
- YTD
- -100.00%
- 1 year
- -100.00%
- Open
- 134.49
- Prev close
- 134.50
- Mkt cap
- 0
- Vol
- 1.37M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 134.47
- High
- 134.51
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 3, 2018
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
May 3, 2018
Expected May 3, 2018. Consensus EPS estimate 0.00.
Financials — quick view
OA Revenue — quarterly 1.31B
OA Net income — quarterly 101.00M
OA EPS — quarterly 1.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 3, 2018 | Mar 1, 2018 | 1.50 | — | — | — |
| Feb 22, 2018 | Dec 1, 2017 | 1.84 | — | — | — |
| Nov 2, 2017 | Sep 1, 2017 | 1.56 | — | — | — |
| Aug 3, 2017 | Jun 1, 2017 | 1.45 | — | — | — |
| May 11, 2017 | Mar 1, 2017 | 1.36 | — | — | — |
| Mar 8, 2017 | Dec 1, 2016 | 1.45 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2017 | Credit Suisse | down | Outperform | Neutral |
| Oct 5, 2017 | Wells Fargo | down | Outperform | Market Perform |
| Oct 5, 2017 | Jefferies | down | Buy | Hold |
| Sep 18, 2017 | SunTrust Robinson Humphrey | down | Buy | Hold |
| Sep 18, 2017 | Argus | down | Buy | Hold |
| Aug 13, 2017 | Argus | up | Hold | Buy |
News
- Omnicom Advertising Announces Leadership Transition
- The Hackett Group® Announces Winners of the 2026 Hackett Innovation Awards
- Eli Lilly's Retatrutide Shows Promising Results in Obesity and Osteoarthritis Trial
- Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
- Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
- Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
- Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs
- Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
- Play Offense With This Defense ETF
- Orbital ATK to Announce Second Quarter 2017 Financial Results on August 3
Your note
Sign in to keep a note on OA — it syncs with the Stock Master app.